Fulgent Genetics

Fulgent Genetics Current Liabilities

The Current Liabilities of Fulgent Genetics (FLGT) as of Oct 11, 2026 is -53.91 M USD. In the previous year, Current Liabilities was 67.75 M USD — a change of -179.58% (lower).

Current Liabilities

-53.91 MUSD

YoY

-179.58%

Last updated:

Current Liabilities of Fulgent Genetics is 2025 -53.91 M USD. Current Liabilities of Fulgent Genetics was 2024 67.75 M USD. It decreases by -179.58% lower compared to the previous year.

The Fulgent Genetics Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
4.14 M USD
Jan 1, 2019
5.13 M USD
Jan 1, 2020
58.74 M USD
Jan 1, 2021
88.15 M USD
Jan 1, 2022
99.91 M USD
Jan 1, 2023
79.36 M USD
Jan 1, 2024
67.75 M USD
Jan 1, 2025
-53.91 M USD
The Fulgent Genetics Current Liabilities history
YEARCurrent LiabilitiesYoY
-53.91 MUSD-179.58%
67.75 MUSD-14.64%
79.36 MUSD-20.57%
99.91 MUSD+13.35%
88.15 MUSD+50.08%
58.74 MUSD+1,044.04%
5.13 MUSD+24.07%
4.14 MUSD+6.10%
3.90 MUSD+8.57%
3.59 MUSD+305.42%
886,000.00USD+65.30%
536,000.00USD—
Access this data via the Eulerpool API

Fulgent Genetics Stock analysis

What does Fulgent Genetics do? Fulgent Genetics Inc. is a US company founded in 2011 by Jianxing (Justin) Liu and Ming Hsieh. The company has undergone remarkable development and is now active in the field of genomics and genetics. Fulgent Genetics' business model is based on the development and distribution of solutions for the diagnosis of genetic diseases. The company offers a variety of products and services that enable doctors, clinics, and laboratories to make effective diagnoses based on genetics. One of Fulgent Genetics' main divisions is the Clinical Diagnostics department, which offers a wide range of diagnostic products that allow for both molecular diagnoses and the creation of clinical profiles for patients. This enables doctors and clinics to quickly and accurately detect and treat specific diseases. Another important division of Fulgent Genetics is the Research department, which focuses on the discovery and development of new technologies and testing procedures. These technologies and procedures are of great interest to the scientific community and are used in research or clinical studies. Fulgent Genetics also offers a Pharmacogenomics department, which is a growing segment in the personalized medicine market. The goal here is to tailor medications to the patient's genetic makeup. Fulgent Genetics' technology allows for the analysis of a patient's current genetic makeup and recommends medications based on that. Another important area of Fulgent Genetics is the direct-to-consumer sales of tests. This is particularly significant in the field of ancestry and genealogy research. Fulgent Genetics offers a variety of tests in this area and has already achieved great success. Overall, Fulgent Genetics offers a wide range of products and services mainly focused on the diagnosis of genetic diseases. However, the company also goes beyond that and provides solutions for a wide range of customers and applications. Fulgent Genetics is based in the US and has experienced rapid growth since its founding. The company's success is also reflected in the many awards it has received. It has been recognized multiple times and has established a reputation as one of the leading biotechnology companies in the world. Fulgent Genetics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Fulgent Genetics stock

Current Liabilities of Fulgent Genetics is -53.91 M USD in 2025.

Current Liabilities of Fulgent Genetics changed from 67.75 M USD to -53.91 M USD, representing a -179.58% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Fulgent Genetics since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Fulgent Genetics historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Fulgent Genetics

All Key Metrics — Fulgent Genetics